Skip to main
ESPR
ESPR logo

Esperion Therapeutics (ESPR) Stock Forecast & Price Target

Esperion Therapeutics (ESPR) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 24%
Buy 19%
Hold 52%
Sell 5%
Strong Sell 0%

Bulls say

Esperion Therapeutics has demonstrated significant financial momentum, highlighted by a 53% increase in product revenue to $31.1 million for the quarter, driven by remarkable retail prescription growth of 12% from the previous quarter and 44% compared to the same quarter last year. The company benefits from increased prescription growth in Europe, with Daiichi Sankyo Europe's efforts contributing to a 19% sequential rise in royalty revenues to $8.9 million based on NILEMDO and NUSTENDI sales, reflecting a robust market presence. Furthermore, improvements in preferred commercial and Medicare coverage exceeding 92% and 65%, respectively, indicate strong confidence from healthcare providers, suggesting positive sales expectations for the future.

Bears say

Esperion Therapeutics Inc. faces a challenging financial outlook due to a history of consistent losses and the absence of a track record for profitability. Recent reports indicate that the company has lowered its sales estimates for the current year, reflecting growing concerns over demand for its products amid potential competitive threats. Additionally, the risk of breakthrough therapies rendering Esperion's offerings obsolete adds further uncertainty, thereby impacting the company's long-term viability and market position.

Esperion Therapeutics (ESPR) has been analyzed by 21 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 19% recommend Buy, 52% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Esperion Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Esperion Therapeutics (ESPR) Forecast

Analysts have given Esperion Therapeutics (ESPR) a Buy based on their latest research and market trends.

According to 21 analysts, Esperion Therapeutics (ESPR) has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Esperion Therapeutics (ESPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.